To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT03081247 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Internal Study team decision not to proceed.

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: BGF 320/14.4/9.6 µg MDI
DRUG: BFF 320/9.6 µg

Sponsor

Pearl Therapeutics, Inc.